Evidence map›Paper›PMID 39827971›Full record

ArticleEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences2025

Optimized PLGA encapsulated SA-2 nanosuspension exhibits sustained intraocular pressure reduction in the mouse microbead occlusion model of ocular hypertension.

Charles E Amankwa, Biddut DebNath, Jennifer H Pham, Gretchen A Johnson, Wei Zhang, Amalendu Ranjan, Dorota L Stankowska, Suchismita Acharya

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Charles E AmankwaDepartment of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX 76107, USA; North Texas Eye Research Institute, University of North Texas Health Science Center, Fort Worth, TX 76107, USA.
Biddut DebNathDepartment of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX 76107, USA; North Texas Eye Research Institute, University of North Texas Health Science Center, Fort Worth, TX 76107, USA.
Jennifer H PhamNorth Texas Eye Research Institute, University of North Texas Health Science Center, Fort Worth, TX 76107, USA; Department of Microbiology, Immunology and Genetics, University of North Texas Health Science Center, Fort Worth, TX 76107, USA.
Gretchen A JohnsonNorth Texas Eye Research Institute, University of North Texas Health Science Center, Fort Worth, TX 76107, USA; Department of Microbiology, Immunology and Genetics, University of North Texas Health Science Center, Fort Worth, TX 76107, USA.
Wei ZhangNorth Texas Eye Research Institute, University of North Texas Health Science Center, Fort Worth, TX 76107, USA; Department of Microbiology, Immunology and Genetics, University of North Texas Health Science Center, Fort Worth, TX 76107, USA.
Amalendu RanjanDepartment of Microbiology, Immunology and Genetics, University of North Texas Health Science Center, Fort Worth, TX 76107, USA.
Dorota L StankowskaNorth Texas Eye Research Institute, University of North Texas Health Science Center, Fort Worth, TX 76107, USA; Department of Microbiology, Immunology and Genetics, University of North Texas Health Science Center, Fort Worth, TX 76107, USA. Electronic address: dorota.stankowska@unthsc.edu.
Suchismita AcharyaDepartment of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX 76107, USA; North Texas Eye Research Institute, University of North Texas Health Science Center, Fort Worth, TX 76107, USA. Electronic address: suchismita.acharya@unthsc.edu.

Funding

Sex differences in in vitro and in vivo glaucoma models may predict gender specific dose adjustment needsR01EY029823 · NEI · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · PI ACHARYA, SUCHISMITA, STANKOWSKA, DOROTA LUIZA · 2020 to 2024
$2.0M
NEI NIH HHS R01 EY029823
6 · The paper itself

Abstract

Elevated intraocular pressure (IOP) is implicated in the structural and functional damage to the retinal ganglion cells (RGCs) in primary open-angle glaucoma (POAG). Topical IOP lowering agents provide short-term relief, necessitating frequent dosing. Moreover, non-adherence to frequent eyedrops administration contributes significantly to visual field loss and worsens the disease outcome. We optimized the poly (lactic-co-glycolic acid) (PLGA) nanoparticles encapsulation of hybrid antioxidant-nitric oxide donor SA-2 (SA-2NP), investigated its bioavailability, duration of IOP lowering efficacy, and effects on retinal function in the microbead model of ocular hypertension (OHT). SA-2 was bioavailable in the anterior and posterior segments after 1, 8, and 24 h post-single topical eyedrop administration. SA-2NP significantly lowered IOP (∼25-34%) and preserved the RGC function after weekly eyedrop administration for 3 weeks in C57BL/6J mice. In conclusion, the optimized SA-2NP formulation demonstrated optimal bioavailability, ocular safety, and prolonged IOP-lowering efficacy in the mouse microbead occlusion model of OHT.

Indexed as

Antihypertensive AgentsAntioxidantsIntraocular PressureNanoparticlesNitric Oxide DonorsOcular HypertensionPolyglycolic AcidPolylactic Acid-Polyglycolic Acid CopolymerAnimalsBiological AvailabilityDisease Models, AnimalMaleMiceMice, Inbred C57BLRetinal Ganglion CellsSuspensionsAntihypertensive AgentsAntioxidantsNitric Oxide DonorsPolyglycolic AcidPolylactic Acid-Polyglycolic Acid CopolymerSuspensionsbioavailabilityintraocular pressurePLGA nanoparticlesprimary open-angle glaucomaretinal protectionSA-2sustained release

Identifiers

PMID39827971
PMCPMC13179673

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.